Drug discrimination in neurobiology

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 2, 1999, Pages 337-345

  Colpaert, F C ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Drug discrimination; Neurobiology; Review

Indexed keywords

LOPERAMIDE; LYSERGIDE; NEUROTRANSMITTER RECEPTOR; OPIATE RECEPTOR; PIRENPERONE; PSYCHEDELIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR;

ADDICTION; BEHAVIOR; CHRONIC PAIN; CONFERENCE PAPER; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERANCE; METHODOLOGY; NEUROBIOLOGY; NONHUMAN; OPIATE ADDICTION; PATHOLOGY; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REINFORCEMENT; SENSITIZATION; SIGNAL TRANSDUCTION; STIMULUS GENERALIZATION; TRAINING;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); HUMANS; NEUROBIOLOGY; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 0032840702     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00047-7     Document Type: Conference Paper

References (166)

1. Altman J.L., Albert J., Milstein S.L., Greenberg I. Drugs as discriminable events in humans. Lal H. Discriminative stimulus properties of drugs. 1977;187-206 Plenum, New York.
2. Amrick C.L., Bennett D.A. N-Methyl-D-aspartate produces discriminative stimuli in rats. Life Sci. 40:1987;585-591.
3. Ariëns, E. J.: The mode of action of biologically active compounds. In: Molecular pharmacology, vol. 1. New York: Academic Press; 1964.
4. Balster R.L. Abuse potential evaluation of inhalants. Drug Alcohol Depend. 19:1987;7-15.
5. Barrett R.J., Steranka L.R. Drug discrimination in rats. Evidence for amphetamine-like cue state following chronic haloperidol Pharmacol. Biochem. Behav. 18:1983;611-617.
6. Barrett R.J., White D.K., Caul W.F. Tolerance, withdrawal and supersensitivity to dopamine mediated cues in a drug-drug discrimination. Psychopharmacology (Berlin). 109:1992;63-67.
7. Barry H.I., Krimmer E.C. Discriminable stimuli produced by alcohol and other CNS depressants. Lal H. Discriminative stimulus properties of drugs. 1977;73-92 Plenum, New York.
8. Bartoletti M., Gaiardi M., Gubellini C., Bacchi A., Babbini M. Time-dependent generalization of morphine stimulus properties to meperidine. Antagonism by naloxone Pharmacol Biochem. Behav. 34:1989;429-431.
9. Bennett D.A., Lal H. Discriminative stimulus properties of the vasodilator, hydralazine. Differential generalization with alpha-one and alpha-two adrenoreceptor drugs Prog. Neuropsychopharmacol. Biol. Psychiatry. 6:1982;17-26.
10. Bertalmio A.J., Woods J.H. Differentiation between mu and kappa receptor mediated effects in opioid drug discrimination. Apparent pA2 analysis J. Pharmacol. Exp. Ther. 243:1987;591-597.
11. Bickel W.K., Bigelow G.E., Preston K.L., Liebson I.A. Opioid drug discrimination in humans. Stability, specificity and relation to self-reported drug effect J. Pharmacol. Ther. 251:1989;1053-1063.
12. Coffin V.L., Carney J.M. Behavioral pharmacology of adenosine analogs. Daly J.W., Kuroda Y., Phillis J.W., Shimizu H., Ui M. Physiology and pharmacology of adenosine derivatives. 1983;267-274 Raven, New York.
13. Colpaert F.C., Lal H., Niemegeers C.J.E., Janssen P.A.J. Investigations on drug produced and subjectively experienced discriminative stimuli. 1. The fentanyl cue, a tool to investigate subjectively experienced narcotic drug actions. Life Sci. 16:1975;705-716.
14. Colpaert F.C., Niemegeers C.J.E., Lal H., Janssen P.A.J. Investigations on drug produced and subjectively experienced discriminative stimuli. 2. Loperamide, an antidiarrheal devoid of narcotic cue producing actions. Life Sci. 16:1975;717-728.
15. Colpaert F.C., Niemegeers C.J.E., Kuyps J.J.M.D., Janssen P.A.J. Apomorphine as a discriminative stimulus, and its antagonism by haloperidol. Eur. J. Pharmacol. 32:1975;383-386.
16. Colpaert F.C., Desmedt L.K.C., Janssen P.A.J. Discriminative stimulus properties of benzodiazepines, barbiturates and pharmacologically related drugs; Relation to some intrinsic and anticonvulsant effects. Eur. J. Pharmacol. 37:1976;113-123.
17. Colpaert F.C., Kuyps J.J.M.D., Niemegeers C.J.E., Janssen P.A.J. Discriminative stimulus properties of fentanyl and morphine. Tolerance and dependence Pharmacol. Biochem. Behav. 5:1976;401-408.
18. Colpaert F.C., Leysen J.E.M.F., Niemegeers C.J.E., Janssen P.A.J. Blockade of apomorphine's discriminative stimulus properties. Relation to neuroleptic activity in neuropharmacological and biochemical assays Pharmacol. Biochem. Behav. 5:1976;671-679.
19. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Theoretical and methodological considerations on drug discrimination learning. Psychopharmacologia. 46:1976;164-177.
20. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. On the ability of narcotic antagonists to produce the narcotic cue. J. Pharmacol. Exp. Ther. 197:1976;180-187.
21. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. The narcotic discriminative stimulus complex. Relation to analgesic activity J. Pharmacol. Pharmacol. 28:1976;183-187.
22. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Discriminative stimulus properties of analgesic drugs. Narcotic versus non-narcotic analgesics Arch. Int. Pharmacodyn. Thér. 220:1976;329-332.
23. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Fentanyl and apomorphine. Asymmetrical generalization of discriminative stimulus properties Neuropharmacology. 15:1976;541-545.
24. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Cocaine cue in rats as it relates to subjective drug effects. A preliminary report Eur. J. Pharmacol. 40:1976;195-199.
25. Colpaert F.C., Wauquier A., Lal H., Niemegeers C.J.E. Experimental approach to the evaluation of drug abuse liability. Van Bever W., Lal H. Synthetic antidiarrheal drugs. 1976;251-267 Marcel Dekker Inc, New York.
26. Colpaert F.C. Drug-produced cues and states. Some theoretical and methodological inferences Lal H. Discriminative stimulus properties of drugs. 1977;5-21 Raven Press, New York.
27. Colpaert F.C. Narcotic cue and narcotic state. Life Sci. 20:1977;1097-1108.
28. Colpaert F.C. Discriminative stimulus properties of narcotic analgesic drugs. Pharmacol. Biochem. Behav. 9:1978;863-887.
29. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Narcotic cuing and analgesic activity of narcotic analgesics. Associative and dissociative characteristics Psychopharmacology (Berlin). 57:1978;21-26.
30. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Neuroleptic interference with the cocaine cue. Internal stimulus control of behaviour and psychosis Psychopharmacology (Berlin). 58:1978;247-255.
31. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Studies on the regulation of sensitivity to the narcotic cue. Neuropharmacology. 17:1978;705-713.
32. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Changes of sensitivity to the cuing properties of narcotic drugs as evidenced by generalization and cross-generalization experiments. Psychopharmacology (Berlin). 58:1978;257-262.
33. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Discriminative stimulus properties of cocaine and d-amphetamine, and antagonism by haloperidol. A comparative study Neuropharmacology. 17:1978;937-942.
34. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Nociceptive stimulation prevents development of tolerance to narcotic analgesia. Eur. J. Pharmacol. 49:1978;335-336.
35. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Factors regulating drug cue sensitivity. A long-term study on the cocaine cue. Colpaert F.C., Rosecrans J.A. Stimulus properties of drugs. Ten years of progress:1978;281-299 Elsevier/North Holland Biomedical Press, Amsterdam.
36. Colpaert, F. C.: Rosecrans, J. A., eds. Stimulus properties of drugs: Ten years of progress. Amsterdam: Elsevier/North Holland Biomedical Press; 1978.
37. Colpaert F.C. Narcotic cue, narcotic analgesia, and the tolerance problem. The regulation of sensitivity to drug cues and to pain by an internal cue processing model Colpaert F.C., Rosecrans J.A. Stimulus properties of drugs. Ten years of progress:1978;301-321 Elsevier/North Holland Biomedical Press, Amsterdam.
38. Colpaert F.C. Can chronic pain be suppressed despite purported tolerance to narcotic analgesia. Life Sci. 24:1979;1201-1210.
39. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Discriminative stimulus properties of cocaine. Neuropharmacological characteristics as derived from stimulus generalization experiments Pharmacol. Biochem. Behav. 10:1979;535-546.
40. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine antagonists. Eur. J. Pharmacol. 58:1979;505-509.
41. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Factors regulating drug cue sensitivity. Limits of discriminability and the role of a progressively decreasing training dose in fentanyl-saline discrimination J. Pharmacol. Exp. Ther. 2:1980;474-480.
42. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors. A possible role for B-phenylethylamine in the cocaine cue Pharmacol. Biochem. Behav. 13:1980;513-517.
43. Colpaert F.C., Janssen P.A.J. Factors regulating drug cue sensitivity. The effect of frustrative non-reward in fentanyl-saline discrimination Arch. Int. Pharmacodyn. Ther. 254:1981;241-251.
44. Colpaert F.C., Janssen P.A.J. Factors regulating drug cue sensitivity. The effects of dose ratio and absolute dose level in the case, of fentanyl dose-dose discrimination Arch. Int. Pharmacodyn. Ther. 258:1982;283-299.
45. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. A drug discrimination analysis of lysergic acid diethylamide. In vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD-antagonist J. Pharmacol. Exp. Ther. 221:1982;206-214.
46. Colpaert F.C., Janssen P.A.J. The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat. Antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist Neuropharmacology. 22:1983;993-1000.
47. Colpaert F.C., Janssen P.A.J. A characterization of LSD-antagonist effects of pirenperone in the rat. Neuropharmacology. 22:1983;1001-1005.
48. Colpaert F.C., Janssen P.A.J. Agonist and antagonist effects of prototype opiate drugs in rats discrimination fentanyl from saline. Characteristics of partial generalization J. Pharmacol. Exp. Ther. 230:1984;193-199.
49. Colpaert F.C., Janssen P.A.J. A possible a2-adrenergic component in the in vivo action of pirenperone. Eur. J. Pharmacol. 103:1984;169-171.
50. Colpaert F.C., Janssen P.A.J. Discriminative stimulus properties of xylazine in rat. Discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists J. Pharmacol. Exp. Ther. 235:1985;521-527.
51. Colpaert F.C. Drug discrimination. Behavioural, pharmacological and molecular mechanisms of discriminative drug effects Goldberg S.R., Stolerman I.P. Behavioral analysis of drug dependence. 1986;161-193 Academic Press, New York.
52. Colpaert F.C., Janssen P.A.J. Agonist and antagonist effects of prototype opiate drugs in fentanyl dose-dose discrimination. Psychopharmacology (Berlin). 90:1986;222-228.
53. Colpaert F.C. Drug discrimination. Methods of manipulation, measurement and analysis Bozarth M.A. Methods of assessing the reinforcing properties of abused drugs. 1987;341-372 Springer Verlag, New York.
54. Colpaert F.C. Evidence that adjuvant arthritis in the rat is associated with chronic pain. Pain. 28:1987;201-202.
55. Colpaert F.C. Intrinsic activity and discriminative effects of drugs. Colpaert F.C., Balster R.I. Transduction mechanisms of drug stimuli. 1988;154-160 Springer Verlag, Berlin.
56. Colpaert F.C. The discriminative response. An elementary particle of behavior Behav. Pharmacol. 2:1991;283-286.
57. 1A agonist and potential anxiolytic agent Drug. Dev. Res. 26:1992;21-48.
58. Colpaert F.C. Drug discrimination. No evidence for tolerance to opiates Pharmacol. Rev. 47:1995;605-629.
59. Colpaert F.C., Koek W. Empirical evidence that the state dependence and drug discrimination paradigms can generate different outcomes. Psychopharmacology (Berlin). 120:1995;272-279.
60. Colpaert F.C. System theory of pain and of opiate analgesia. No tolerance to opiates Pharmacol. Rev. 48:1996;355-402.
61. Cone E.J., Mcquinn R.L. Shannon, H. E. Structure-activity relationship studies of phencyclidine derivatives in rats J. Pharmacol. Exp. Ther. 228:1984;147-153.
62. Cunningham K.A., Appel J.B. Hallucinogenic and non-hallucinogenic 5-HT agonists. Differences in subjective effects parallel differences in receptor dynamics Rech R.H., Gudelsky G.A. 5-HT agonists as pychoactive agents. 1988;217-238 NPP Books, Ann Arbor.
63. De Vry J., Koek W., Slangen J.L. Effects of drug-induced differences in reinforcement frequency on discriminative stimulus properties of fentanyl. Psychopharmacology (Berlin). 83:1984;257-261.
64. 1A receptor agonists. Recent developments and controversial issues Psychopharmacolgy (Berlin). 121:1995;1-26.
65. Druhan J.P., Fibiger H.C., Phillips A.G. Amphetamine-like stimulus properties produced by electrical stimulation of reward sites in the ventral tegmental area. Behav. Brain Res. 38:1990;175-184.
66. 2C receptors. Psychopharmacology (Berlin). 136:1998;409-414.
67. Eich J.E. State-dependent retrieval of information in human episodic memory. Birnbaum I.M., Parker E.S. Alcohol and human memory. 1977;Erlbaum, Hillsdale, NJ.
68. Evans E.B., Balster R.L. CNS depressant effects of volatile organic solvents. Neurosci. Biobehav. Rev. 15:1991;233-241.
69. France C.P., Jacobson A.E., Woods J.H. Discriminative stimulus effects of reversible and irreversible opiate agonists. Morphine, oxymorphazone and buprenorphine J. Pharmacol. Exp. Ther. 230:1984;652-657.
70. France C.P., Woods J.H. Opiate agonist-antagonist interactions. Applications of a three-key drug discrimination procedure J. Pharmacol Exp. Ther. 234:1985;81-89.
71. France C.P., Adams J.U., Woods J.H. Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons. Neuropharmacology. 26:1987;541-548.
72. France C.P. Drug discrimination as a model for studying opioid dependence and withdrawal in animals. Palomo T., Archer T. Strategies for studying brain disorders. Depressive, anxiety and drug abuse disorders:1994;281-301 Farrand Press, Spain.
73. Gellert V.F., Holtzman S.G. Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J. Pharmacol. Exp. Ther. 211:1979;596-605.
74. Glennon R.A., Young R., Rosecrans J.A., Kallman M.J. Hallucinogenic agents as discriminative stimuli. A correlation with serotonin receptor affinities Psychopharmacology (Berlin). 68:1980;154-158.
75. Glennon R.A. Hallucinogenic phenylisopropylamines. Stereochemical aspects Smith D.F. CRC handbook of stereoisomers. Drugs in psychopharmacology:1984;327-368 CRC Press, Boca Raton, FL.
76. Glennon R.A., Young R., Hauck A.E., McKenney J.D. structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol. Biochem. Behav. 21:1984;895-901.
77. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2505-2511.
78. 1A agonist 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH DPAT). Pharmacol. Biochem. Behav. 25:1986;135-139.
79. Glennon R.A., Young R. The study of structure-activity relationships using drug discrimination methodology. Bozarth M.A. Methods of assessing the reinforcing properties of abused drugs. 1987;373-390 Springer Verlag, New York.
80. Goudie A.J. Temporal parameters of the discriminative stimulus and rate-suppressant properties of the psychostimulant dl-cathinone possible relevance to prediction of drug dependence potential. IRCS Med. Sci. 13:1985;966-967.
81. Herling S., Woods J.H. Discriminative stimulus effects of narcotics. Evidence for multiple receptor-mediated actions Life Sci. 28:1981;1571-1584.
82. Herling S., Coale E.H., Hein D.W., Winger G., Woods J.H. Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrophan in the pigeon. Psychopharmacology (Berlin). 73:1981;286-291.
83. Himmelweit, F., ed. The collected papers of Paul Ehrlich. London: Pergamon Press; 1956.
84. Ho B.T., Silverman P.B. Stimulants as discriminative stimuli. Colpaert F.C., Rosecrans J.A. Stimulus properties of drugs. Ten years of progress:1978;53-68 Elsevier-North Holland, Amsterdam.
85. Holohean A.M., White F.J., Appel J.B. Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur. J. Pharmacol. 81:1982;595-602.
86. Holtzman S.G. Phencyclidine (PCP)-like discriminative effects of opioids in the rat. Fed. Proc. 39:1980;994.
87. Holtzman S.G. Discriminative stimulus properties of opiate drugs. Cooper S.J. Theory in psychopharmacology. 1983;1-45 Academic Press, New York.
88. Holtzman S.G. Discriminative stimulus properties of opioids that interact with mu, kappa and PCP/sigma receptors. Seiden L.S., Balster R.L. Behavioral pharmacology. The current status:1985;131-147 Alan R. Liss, New York.
89. Holtzman S.G. Discriminative stimulus effects of morphine withdrawal in the dependent rat. Suppression by opiate and nonopiate drugs J. Pharmacol. Exp. Ther. 233:1985;80-86.
90. Holtzman S.G. Discriminative stimulus properties of caffeine in the rat noradrenergic mediation. J. Pharmacol. Exp. Ther. 239:1986;706-714.
91. Holtzman S.G., Locke K.W. Neural mechanisms of drug stimuli. Experimental approaches Colpaert F.C., Balster R.L. Transduction mechanisms of drug stimuli. 1988;139-153 Springer Verlag, Berlin.
92. Jackson A., Koek W., Colpaert F.C. NMDA antagonists make learning and recall state-dependent. Behav. Pharmacol. 3:1992;415-421.
93. Jarbe T.U.C., Johansson J.O., Henriksson B.G. Characteristics of tetrahydrocannabinol (THC)-produced discrimination in rats. Psychopharmacology (Berlin). 48:1976;181-187.
94. Jarbe T.U.C. Alcohol-discrimination in gerbils. Interactions with bemegride, DH-524, amphetamine, and delta-9-THC Arch. Int. Pharmacodyn. 227:1977;118-129.
95. Jarbe T.U.C., Hiltunen A.J., Mechoulam R. Subjectively experienced cannabis effects in animals. Drug Dev. Res. 16:1989;385-393.
96. Johansson J.O., Jarbe T.U.C. Physostigmine as a discriminative cue in rats. Arch. Int. Pharmacodyn. 219:1976;97-102.
97. Jung M., Costa L., Shearman G.T., Kelly P.H. Discriminative stimulus properties of muscarinic agonists. Psychopharmacology (Berlin). 93:1987;139-145.
98. Jung M., Perio A., Terranova J.P., Worms P., Biziere K. Effects of intracerebroventricular pirenzepine on muscarinic discriminations in rats. Eur. J. Pharmacol. 139:1987;111-116.
99. Kamien J.B., Goldberg L.I., Woolverton W.L. Discriminative stimulus properties of D1 and D2 dopamine agonists in rats. J. Pharmacol. Exp. Ther. 242:1987;804-811.
100. Koek W., Slangen J.L. Effects of reinforcement differences between drug and saline sessions on discriminative stimulus properties of fentanyl. Colpaert F.C., Slangen J.L. Drug discrimination. Applications in CNS pharmacology:1982;343-354 Elsevier, Amsterdam.
101. Koek W., Woods J.H. Partial generalization in pigeons trained to discriminate morphine from saline. Drug Dev. Res. 16:1989;169-181.
102. Koek W., Colpaert F.C., Vignon J. Effects of phencyclidine-type drugs in rats discriminating fentanyl from saline. Pharmacological and behavioral characterization of intermediate levels of drug lever selection J. Pharmacol. Exp., Ther. 264:1993;746-756.
103. Koek W., Kleven M.S., Colpaert F.C. Effects of the NMDA antagonist, dizocilpine, in various drug discriminations. Characterization of intermediate levels of drug lever selection Behav. Pharmacol. 6:1995;590-600.
104. 1A agonist with marked anxiolytic and antidepressant potential. J. Pharmacol. Exp. Ther. 287:1998;266-283.
105. Kuhn D.M., White F.J., Appel J.B. Discriminative stimulus properties of hallucinogens. Behavioral assay of drug action Lal H. Discriminative stimulus properties of drugs. 1977;137-154 Plenum, New York.
106. Levesque T.R., Locke K.W. Discriminative stimulus effects of melatonin in the rat. Psychopharmacology (Berlin). 116:1994;167-172.
107. 2A receptors on interneurons in rat piriform cortex. J. Pharmacol. Exp. Ther. 278:1996;1373-1382.
108. Martin G.M., Bechara A., van der Kooy D. The perception of emotion. Parallel neural processing of the affective and discriminative properties of opiates Psychobiology. 19:1991;147-152.
109. McMillan D.E., Wenger G.R. Bias of phencyclidine discrimination by the schedule of reinforcement. J. Exp. Anal. Behav. 42:1984;51-66.
110. Meert T.F., De Haes P., Janssen P.A.J. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology (Berlin). 97:1989;206-212.
111. Meert T.F., de Haes P.L.A.J., Vermote P.C.M., Janssen P.A.J. Pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug. Dev. Res. 19:1990;353-373.
112. Melton P.M., Riley A.L. Receptor mediation of the stimulus properties of cholecystokinin. Pharmacol. Biochem. Behav. 48:1994;275-279.
113. Merskey H. The definition of pain. Eur. J. Psychiatry. 6:1991;153-159.
114. Milligan G., Bond R.A., Lee M. Inverse agonism. Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 6:1995;10-13.
115. Nielsen E.B., Jepsen S.A. Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur. J. Pharmacol. 111:1985;167-176.
116. Nielsen E.B., Scheel-Kruger J. Cueing effects of amphetamine and LSD. Elicitation by direct microinjections of the drugs into the nucleus accumbens Eur. J. Pharmacol. 125:1986;85-92.
117. Oberlender R.A., Kothari P.J., Nichols D.E., Zabik J.E. Substituent branching in phenethylamine type hallucinogens. A comparison of 1-(2,5-dimethoxy-4-(2-butyl)phenyl)-2-aminopropane and 1-(2,5-dimethoxy-4-(2-methylpropyl)phenyl)-2-aminopropane J. Med. Chem. 27:1984;788-792.
118. O'Donnell J.M. Pharmacological characterization of the discriminative stimulus effects of clenbuterol in rats. Pharmacol. Biochem. Behav. 58:1997;813-818.
119. Overton D.A. State-dependent learning produced by depressant and atropine-like drugs. Psychopharmacology (Berlin). 10:1966;6-31.
120. Overton, D. A.: State-dependent learning produced by alcohol and its relevance to alcoholism. In: Kissin, B.; Begleiter, H., eds. The biology of alcoholism, vol. 2. Physiology and behavior. New York: Plenum Press; 1972:193-217.
121. Overton D.A. Experimental methods for the study of state-dependent learning. Fed. Proc. 33:1974;1800-1813.
122. Overton D.A. Discriminable effects of antihistamine drugs. Arch. Int. Pharmacodyn. 232:1978;221-226.
123. Overton D.A. Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm. Psychopharmacology (Berlin). 76:1982;385-395.
124. Pauwels P.J., Wurch T. Amino acid domains involved in constitutive activation of G-protein-coupled receptors. Mol. Neurobiol. 17:1998;109-135.
125. Poling A.D., White F.J., Appel J.B. Discriminative stimulus properties of phencyclidine. Neuropharmacology. 18:1979;459-463.
126. Preston K.L. Drug discrimination methods in human drug abuse liability evaluation. Br. J. Addict. 86:1991;1587-1594.
127. Preston K.L., Bigelow G.E. Subjective and discriminative effects of drugs. Behav. Pharmacol. 2:1991;293-313.
128. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioural and pharmacokinetic studies on nicotine, cytosine and lobeline. Neuropharmacology. 29:1990;619-624.
129. Rees D.C., Knisely J.S., Balster R.L., Jordan S., Breen T.J. Pentobarbital like discriminative properties of halothane, 1,1,1-trichloroethane, isoamyl nitrite, flurothyl and oxazepam in mice. J. Pharmacol. Exp. Ther. 241:1987;507-515.
130. Rees D.C., Knisely J.S., Breen T.J., Balster R.L. Toluene halothane 1,1,1-trichloroethane and oxazepam produce ethanol like discriminative stimulus effects in mice. J. Pharmacol. Exp. Ther. 243:1987;931-937.
131. Riley A.L., Kautz M.A., Geter B., Smurthwaite S.T., Pournaghash S., Melton P.M., Feffari C.M. A demonstration of the graded nature of the generalization function of drug discrimination learning within the conditioned taste aversion procedure. Behav. Pharmacol. 2:1991;323-334.
132. Riley A.L. Use of drug discrimination learning in behavioural toxicology. Classification and characterization of toxins Chang L.W., Slikker W.R. Neurotoxicology. Approaches and methods:1995;309-321 Academic Press, San Diego.
133. Rosecrans J.A., Chance W.T. Cholinergic and noncholinergic aspects of the discriminative stimulus properties of nicotine. Lal H. Discriminative stimulus properties of drugs. 1977;155-185 Plenum, New York.
134. Rosecrans J.A., Chance W.T. The discriminative stimulus properties of n- and m-cholinergic receptor stimulants. Ho B.T., Richards D.W. III, Chute D.L. Drug discrimination and state dependent learning. 1978;119-130 Academic Press, New York.
135. Sanger D.J. Behavioural effects of the alpha-2 adrenoreceptor antagonists idazoxan and yohimbine in rats. Comparisons with amphetamine Psychopharmacology (Berlin). 96:1988;243-249.
136. Schuh K.J., Schaal D.W., Thompson T., Cleary J.P., Billington C.J., Levine A.S. Insulin, 2-deoxy-D-glucose and food deprivation as discriminative stimuli in rats. Pharmacol. Biochem. Behav. 47:1994;317-324.
137. Schuster C.R., Balster R.L. The discriminative stimulus properties of drugs. Thompson T., Dews P.B. Advances in behavioral pharmacology, vol. 1. 1977;85-138 Academic Press, New York.
138. Schuster C.R., Johanson C. Efficacy, dependence potential and neurotoxicity of anorectic drugs. Seiden L.S., Balster R.L. Behavioral pharmacology. The current status:1985;263-279 Alan R. Liss, New York.
139. Schuster C.R., Johanson C. Relationship between the discriminative stimulus properties and subjective effects of drugs. Colpaert F.C., Balster R.L. Transduction mechanisms of drug stimuli. 1988;161-175 Springer Verlag, Berlin.
140. Shannon H.E., Holtzman S.G. Evaluation of the discriminative effects of morphine in the rat. J. Pharmacol. Exp. Ther. 198:1976;54-65.
141. Shearman G.T., Lal H. Discriminative stimulus properties of pentylenetetrazol and bemegride. Some generalization and antagonism tests Psychopharmacology (Berlin). 64:1979;315-319.
142. Sherrington C.S. The integrative action of the central nervous system. 1906;Constable, London.
143. Spealman R.D., Coffin V.L. Discriminative stimulus effects of adenosine analogs. Mediation by adenosine A2 receptors J. Pharmacol. Exp. Ther. 246:1988;610-618.
144. Stolerman I.P., Pratt J.A., Garcha H.S. Further analysis of the nicotine cue in rats. Colpaert F.C., Slangen J.L. Drug discrimination. Applications in CNS pharmacology:1982;203-210 Elsevier, Amsterdam.
145. Stolerman, I. P.: Psychopharmacology of nicotine: Stimulus effects and receptor mechanisms. In: Iversen, L. L.; Iversen, S. D.; Snyder, S. H., eds. Handbook of psychopharmacology, vol. 19. New York: Plenum; 1987:421-465.
146. Stolerman I.P., Colpaert F.C. The European Behavioural Pharmacology Society. Psychopharmacology (Berlin). 101:1990;289-291.
147. Stolerman I.P. Measures of stimulus generalization in drug discrimination experiments. Behav. Pharmacol. 2:1991;265-282.
148. Stolerman, I. P.; Kamien J. B.: The drug discrimination database on the world wide web. Http://www.dd.database.org ; 1998.
149. Swanson J.M., Kinsbourne M. The 2 × 2 design reconsidered. Limitations imposed by the statistical model Colpaert F.C., Rosecrans J.A. Stimulus properties of drugs. Ten years of progress:1978;467-480 Elsevier/North-Holland Biomedical Press, Amsterdam.
150. Van Ree J.M., Smyth D.G., Colpaert F.C. Dependence creating properties of lipotropin C-fragment (B-endorphin). Evidence for its internal control of behaviour Life Sci. 24:1979;495-502.
151. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther. 271:1994;959-968.
152. Weathersby R.T., Appel J.B. Dopamine D2 receptor mediation of the discriminative stimulus properties of LY 171555 (quinpirole). Eur. J. Pharmacol. 132:1986;87-91.
153. Weingartner H. Human state-dependent learning. Ho B., Richards D.W. III, Chute D.L. Drug discrimination and state-dependent leaming. 1978;363-383 Academic Press, New York.
154. Weissman A. The discriminability of aspirin in arthritic and nonarthritic rats. Pharmacol. Biochem. Behav. 5:1976;583-586.
155. Wessinger W.D., Wenger G.R. The discriminative stimulus properties of barbiturate stereoisomers. Psychopharmacology (Berlin). 92:1987;334-339.
156. White F.J., Kuhn D.M., Appel J.B. Discriminative stimulus properties of quipazine. Neuropharmacology. 16:1977;827-832.
157. Winger G., Herling S. Discriminative stimulus effects of pentobarbital in rhesus monkeys. Tests stimulus generalization and duration of action Psychopharmacology (Berlin). 76:1982;172-176.
158. Winter J.C. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide. The role of 5-hydroxytryptamine J. Pharmacol. Exp. Ther. 204:1978;416-423.
159. Winter J.C. Sedation and the stimulus properties of antihistamines. Pharmacol. Biochem. Behav. 22:1985;15-17.
160. Wood D.M., Emmett-Oglesby M.W. Mediation in the nucleus accumbens of the discriminative stimulus produced by cocaine. Pharmacol. Biochem. Behav. 33:1989;453-457.
161. Woods J.H., Bertalmio A.J., Young A.M., Essman W.D., Winger G. Receptor mechanisms of opioid drug discrimination. Colpaert F.C., Balster R.L. Transduction mechanisms of drug stimuli. 1988;95-106 Springer Verlag, Berlin.
162. Woolverton W.L., Kamien J.B., Goldberg L.I. Effects of selective dopamine receptor agonists in rats trained to discriminate apomorphine from saline. Pharmacol. Biochem. Behav. 22:1985;577-581.
163. Young R., Glennon R.A. Stimulus properties of benzodiazepines. Correlations with binding affinities, therapeutic potency, and structure activity relationships (SAR) Psychopharmacology (Berlin). 93:1987;529-533.
164. Young A.M., Sannerud C.A. Tolerance to drug discriminative stimuli. Goudie A.J., Emmett-Oglesby M.W. Tolerance and sensitization. 1989;221-278 Humana Press, Clifton, NJ.
165. Young A.M. The time is ripe for an experimental analysis of measurement issues. Commentary on Stolerman "Measurement issues in drug discrimination." Behav. Pharmacol. 2:1991;287-291.
166. Zhang L., Barrett J.E. Imipramine as discriminative stimulus. J. Pharmacol. Exp. Ther. 259:1991;1088-1093.